SLC5A2 and type 2 diabetes mellitus: Given that T2DM has been known to have a higher risk of cardiovascular events, significant attention has been paid to the benefit of SGLT2 inhibitors on cardiovascular outcomes in T2DM patients with or without pre-existing cardiovascular disease (Scholtes et al., 2019).